A Multicenter, Phase III, Open-label Study Evaluating the Benefit of a Long-term Effect of MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma After Induction of Response (CR[u] or PR) With MabThera (Rituximab) Containing First-line Regimen
Phase of Trial: Phase III
Latest Information Update: 14 Dec 2015
At a glance
- Drugs Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Roche
- 06 Oct 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 23 Feb 2010 Status changed from active, no longer recruiting to recruiting as reported by Roche record
- 17 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by Roche record.